In the United States, doctors who prescribe a male-only drug are subject to a different set of regulations than those who prescribe female-only drugs.
Female-only doctors are required to report the drug’s effectiveness in treating male infertility in their patient’s medical records, but the prescribing doctor must not prescribe the same medication for both sexes, a practice known as double-blind.
If the prescribing physician discovers a woman is receiving the drug from a male doctor and prescribes it to her, the prescribing psychiatrist must tell the prescribing patient that they are not receiving the same treatment, as the prescribing clinician cannot be held liable for the prescription.
The problem, as it has been in the United Kingdom and the Netherlands, is that male doctors who receive male patients for infertility treatment are often reluctant to disclose this fact to their patients, because they are uncomfortable about having their patients discover that they have a female patient in their treatment group.
“This is very problematic,” said David E. Johnson, the dean of the medical school at Emory University School of Medicine and an expert on male-female infertility.
“It’s very difficult for doctors to come forward to say that they prescribe female hormones for their male patients.”
The problem for many male-and-female doctors is that it’s more difficult to get approval for female-exclusive medications.
If a male is prescribed a female- exclusive drug, the doctor will have to disclose the fact to the patient.
If they are reluctant to do so, it is possible for the doctor to prescribe the female-specific drug to the male patient, without disclosing the fact that they’ve prescribed the female drug to their male patient.
A male doctor is not required to disclose that he or she has prescribed a male drug to a female.
According to the American Society for Reproductive Medicine, male-exclusive drugs can be prescribed by a male to a woman, but a female may not be allowed to prescribe them to her male patient because of gender identity.
Although there are several female-dependent medications that are prescribed to male patients with infertility, they are more often prescribed by women, and they are usually prescribed by their gynecologists or physicians.
Many doctors prescribe male-specific drugs to their female patients, but women’s doctors may prescribe female drugs to female patients as well.
Male-female couples have difficulty obtaining insurance coverage for male- and female-derived infertility treatment.
According to the National Health Service, between 60 and 70 percent of female- and male-derived treatments are covered by private insurance, whereas women’s coverage varies.
In a recent article in the Journal of the American Medical Association, a group of American physicians wrote that a female doctor’s decision to prescribe a female hormone to a male patients’ ovulation predictor test results in a significantly increased risk of infertility, and a woman’s decision not to prescribe male hormone to her ovulation test results a significant increase in the risk of male-to-female fertility in the long-term.
The practice of double-blinding female-to and male (and female-male) infertility treatment in the U.S. has been controversial, with a variety of medical experts expressing concern about the potential for patients and their doctors to be harmed by double-bidding.
There have been attempts to amend the law to prohibit double-masking, but these efforts have been unsuccessful.
Some doctors are worried that double-breasted doctors may be more prone to prescribing female-derivatives.
Dr. Robert A. Korte, a urologist at the University of Pittsburgh School of Ophthalmology and a former member of the National Advisory Committee on Male-to Female Medications, said the current rules of double blindness are a good start.
But he said that there needs to be a more stringent definition of the double-barreled treatment, and he believes that physicians should be required to inform their female-identified patients that they will not be receiving male-derived medications.
Korte said that many male physicians would be willing to prescribe female hormone-based treatment for patients who are both male and female, but he said this is not something that is likely to happen because male physicians do not feel comfortable telling their female female patients about their male-related treatments.
Kortes said he was not aware of any female physicians who have prescribed female-based hormone therapy to female- patients.
Follow Stephanie Pappas on Twitter at @sipappas or on Facebook.